Testosterone Replacement Therapy and Keratosis Pilaris
Testosterone replacement therapy can worsen keratosis pilaris, though this is an uncommon dermatologic side effect. While acne is the most frequently reported skin complication of TRT, there is documented evidence of testosterone-induced generalized keratosis pilaris.
Evidence for Dermatologic Effects
The FDA-approved labeling for testosterone identifies skin and appendage effects including "hirsutism, male pattern of baldness, seborrhea, and acne" 1, but does not specifically list keratosis pilaris. However, a 2023 case report documented the first instance of generalized keratosis pilaris induced by testosterone injections in a 13-year-old boy with CHARGE syndrome 2. This represents direct evidence that testosterone can trigger or worsen this condition.
A comprehensive 2026 scoping review of dermatological adverse effects found that:
- Acne is the most common skin side effect (0.6%-9.1% of patients) 3
- Abnormal hair growth occurs in up to 5.3% of patients 3
- Injectable formulations carry higher rates of dermatologic reactions than topical or oral preparations 3
Clinical Implications
Risk Assessment
The mechanism likely relates to testosterone's effects on follicular keratinization and sebaceous gland activity. Since keratosis pilaris fundamentally involves follicular hyperkeratosis with abnormal desquamation 4, 5, and testosterone stimulates follicular activity, the connection is biologically plausible.
Formulation Considerations
If TRT is medically necessary despite keratosis pilaris concerns, consider topical or oral formulations over injectable testosterone, as injectable forms demonstrate higher rates of cutaneous complications 3. The 2004 NEJM guidelines note that intramuscular injections produce supraphysiologic testosterone peaks that may exacerbate androgen-dependent skin effects 6.
Management Strategy
If keratosis pilaris worsens on TRT:
- First-line topical keratolytics (alpha hydroxy acids, beta hydroxy acids, or urea) can manage symptoms 4
- Consider dose reduction or formulation change
- Monitor for other dermatologic effects (acne, hirsutism) which are more common
Important Caveats
The evidence for testosterone-induced keratosis pilaris is limited to case reports, making it difficult to quantify true incidence. Most dermatologic studies of TRT focus on acne rather than keratosis pilaris 3. The condition may be underreported since it's often considered cosmetically bothersome rather than medically significant, though it can substantially impact quality of life 4.
The decision to continue or initiate TRT should weigh the established benefits for hypogonadism (improved sexual function, bone density, muscle mass, mood) 7 against the relatively minor but real risk of worsening keratosis pilaris, particularly if the patient already has this condition or risk factors (dry skin, atopic dermatitis, adolescence) 5.